June Lee, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
AddressLocation Required, #001
Varies CA 00000
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, DavisM.D.1992School of Medicine
    Johns Hopkins UniversityB.S.1988Chemistry

    Collapse Overview 
    Collapse Overview
    June Lee, MD, is a Professor in the School of Medicine at UCSF. She was the chief architect of the highly successful Clinical and Translational Science Institute's Catalyst Program which serves as an internal UCSF accelerator for therapeutics, devices, diagnostics, and digital health technologies. She also oversaw key strategic partnerships at UCSF to include industry collaborations. She also served as Chair of the Drug, Device, Discovery and Development (D4) workgroup of UC BRAID (University of California Biomedical Research Acceleration Integration and Development) and was previously the Vice-Chair of CTSA Translational Key Function Committee.

    Prior to UCSF, she worked at Genentech where as the therapeutic area head, she led early clinical development programs in Infectious Diseases, Cardiovascular/Metabolic Diseases, and Respiratory Diseases. In that role, she was responsible for the clinical strategy and execution of programs in the early clinical development stages and successfully developed pre-clinical and late stage research projects in a variety of therapeutic areas through IND clearance and early stage clinical proof of concept studies.
    Collapse In The News

    Collapse Research 
    Collapse Research Activities and Funding
    Carbohydrate-based Therapy for Lung Disease
    NIH P01HL128191Sep 1, 2016 - Jul 31, 2021
    Role: Co-Investigator
    Gene Regulation by IL-4 and IL-13 in Airway Cells
    NIH K08HL068591Jan 14, 2002 - Nov 30, 2006
    Role: Principal Investigator
    NIH F32HL009961Dec 30, 1998
    Role: Principal Investigator

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin Exp Allergy. 2014 Jan; 44(1):38-46. Scheerens H, Arron JR, Zheng Y, Putnam WS, Erickson RW, Choy DF, Harris JM, Lee J, Jarjour NN, Matthews JG. PMID: 24131304; PMCID: PMC4204278.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCellsCTClinical Trials
    2. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial. Arthritis Res Ther. 2012 Jan 08; 14(1):R6. Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC. PMID: 22225620; PMCID: PMC3392792.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCellsCTClinical Trials
    3. Racial disparities in asthma-related health outcomes in severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol. 2008 Sep; 101(3):256-63. Haselkorn T, Lee JH, Mink DR, Weiss ST, TENOR Study Group. PMID: 18814448.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    4. The response to combination therapy treatment regimens in severe/difficult-to-treat asthma. Eur Respir J. 2008 Nov; 32(5):1237-42. Campbell JD, Borish L, Haselkorn T, Rasouliyan L, Lee JH, Wenzel SE, Sullivan SD, TENOR Study Group. PMID: 18684845.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    5. Insurance status and asthma-related health care utilization in patients with severe asthma. Ann Allergy Asthma Immunol. 2008 Apr; 100(4):301-7. Peters AT, Klemens JC, Haselkorn T, Weiss ST, Grammer LC, Lee JH, Chen H, TENOR Study Group. PMID: 18450113.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    6. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest. 2007 Dec; 132(6):1882-9. Lee JH, Haselkorn T, Borish L, Rasouliyan L, Chipps BE, Wenzel SE. PMID: 18079222.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    7. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2007 May; 119(5):1156-63. Chipps BE, Szefler SJ, Simons FE, Haselkorn T, Mink DR, Deniz Y, Lee JH, TENOR Study Group. PMID: 17397912.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    8. Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med. 2007 Mar; 101(3):481-9. Miller MK, Lee JH, Miller DP, Wenzel SE, TENOR Study Group. PMID: 16914299.
      View in: PubMed   Mentions: 93     Fields:    Translation:HumansPHPublic Health
    9. TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma. Eur Respir J. 2006 Dec; 28(6):1145-55. Miller MK, Lee JH, Blanc PD, Pasta DJ, Gujrathi S, Barron H, Wenzel SE, Weiss ST, TENOR Study Group. PMID: 16870656.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    10. Gender differences in IgE-mediated allergic asthma in the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study. J Asthma. 2006 Apr; 43(3):179-84. Lee JH, Haselkorn T, Chipps BE, Miller DP, Wenzel SE, Tenor Study Group. PMID: 16754518.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    11. Asthma in older adults: observations from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study. Ann Allergy Asthma Immunol. 2006 Mar; 96(3):406-14. Slavin RG, Haselkorn T, Lee JH, Zheng B, Deniz Y, Wenzel SE, TENOR Study Group. PMID: 16597074.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    12. Interleukin-13 induces dramatically different transcriptional programs in three human airway cell types. Am J Respir Cell Mol Biol. 2001 Oct; 25(4):474-85. Lee JH, Kaminski N, Dolganov G, Grunig G, Koth L, Solomon C, Erle DJ, Sheppard D. PMID: 11694453.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    13. Fatal bilateral chylothorax in mice lacking the integrin alpha9beta1. Mol Cell Biol. 2000 Jul; 20(14):5208-15. Huang XZ, Wu JF, Ferrando R, Lee JH, Wang YL, Farese RV, Sheppard D. PMID: 10866676; PMCID: PMC85969.
      View in: PubMed   Mentions: 112     Fields:    Translation:Animals
    June's Networks
    Concepts (105)
    Derived automatically from this person's publications.
    Co-Authors (5)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department